Immunoglobulin News and Research

RSS

Pre-existing B-cell immunity against SARS-CoV-2 not detected in pre-pandemic samples

A recent study investigates samples solated from unexposed individuals pre-pandemic to determine the presence of pre-existing SARS-CoV-2 B-cell immunity.

22 Feb 2022

New approach for extensive screening of monoclonal antibody clones against multiple myeloma cells

Multiple myeloma (MM) is a largely incurable cancer of plasma cells with an extremely poor prognosis. However, investigators from Japan have recently found that a common component of amino acid transporters, CD98 heavy chain, represents an effective monoclonal antibody target in treating MM.

22 Feb 2022

Lung microbiome alterations and secondary-infections in lethal COVID-19

Researchers examined how an interplay of host and microbial factors weakened immunity leading to secondary infections in COVID-19-infected individuals.

22 Feb 2022

Study suggests anti-SARS-CoV-2 antibodies may persist lifelong post-infection

Researchers attempted to delineate the duration and stability of anti-SARS-CoV-2 antibodies in patients who had recovered from the COVID-19 infection.

22 Feb 2022

Using IgG antibody assay to Identify natural SARS-CoV-2 infection in vaccinees

A recent study published in the journal of Mayo Clinic Proceedings predicted the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) natural infection in vaccinated individuals.

21 Feb 2022

Novel ACE2-blocking antibody protects against all SARS-CoV-2 VOCs

Researchers identify 87G7, a SARS-CoV-2 neutralizing human monoclonal antibody with remarkable broad-spectrum neutralization and protection efficacy.

21 Feb 2022

Study reports potently neutralizing mucosal IgA in saliva of BNT162b2 vaccine recipients

researchers determine the strong neutralizing mucosal component emanating from intramuscular administration of an mRNA vaccine.

21 Feb 2022

Mathematical model of host immune response to SARS-CoV-2 demonstrates that age-related risk factors increased viral load

Researchers evaluated the host immune responses to SARS-CoV-2 and its prolonged symptoms.

21 Feb 2022

Inhalable antibody fragments offer broad protection from SARS-CoV-2 variants

A new study describes a potential new approach to treating COVID-19 in the form of single-chain fragment variable (scFv) antibodies.

20 Feb 2022

Mechanism of fatty-acid coupled adaptive immunity in SARS-CoV-2 revealed

A new study explains how SARS-CoV-2 adapts its immunogenicity to the immune response of the host.

20 Feb 2022

Immunogenicity, efficacy, and safety of BNT162b2 or mRNA1273 fourth dose

A recent study explored the safety, immunogenicity, and VE of the SARS-CoV-2 mRNA BNT162b2 and mRNA1273 vaccines against its Omicron VOC in HCWs in Israel.

18 Feb 2022

Study explores humoral and cellular immunity conferred by second and third COVID-19 BNT162b2 vaccination in elderly

Researchers recently assessed SARS-CoV-2-specific humoral and cellular immune responses induced by the second and third doses of the BNT162b2 COVID-19 messenger ribonucleic acid-based vaccine in the elderly.

17 Feb 2022

mRNA COVID-19 vaccine shown to induce afucosylated antibodies in individuals without prior SARS-CoV-2 exposure

New study findings reveal that the level of afucosylated anti-spike antibodies increases transiently in infection-naïve individuals after the first COVID-19 vaccine dose.

17 Feb 2022

Memory B cell repertoire in a longitudinal cohort of individuals receiving 3 COVID-19 mRNA vaccine doses

Researchers examined the memory B cell repertoire of individuals immunized with three doses of mRNA-based COVID-19 vaccine.

17 Feb 2022

Children with severe COVID-19 show low mucosal neutralizing activity against SARS-CoV-2

A new study examines neutralizing responses to the ancestral variant of SARS-CoV-2, as well as against later variants of concern.

16 Feb 2022

Features of platelet-immune crosstalk in healthy recipients of two doses of mRNA-based SARS-CoV-2 vaccine BNT162b2

Researchers investigated the role of platelets in the adverse immune response against a COVID-19 vaccine.

16 Feb 2022

Neutralizing antibody levels to different SARS-CoV-2 epitopes fluctuate over time

Researchers study antibodies against various SARS-CoV-2 epitopes that may be responsible for neutralizing activities in recovered COVID-19 patients.

15 Feb 2022

Canadian study estimates incidence rate of reinfection in healthcare workers

Researchers from various Canadian institutions document all cases of reinfection discovered during the first year of the project.

15 Feb 2022

Post-vaccination titers of neutralizing antibodies revealed as a moderate predictor of vaccine-induced immunity

In a new study, researchers investigated whether neutralizing antibodies against the SARS-CoV-2 spike protein offered adequate immunity against breakthrough infections among vaccinated individuals.

15 Feb 2022

Real-world data on efficacy and safety of COVID vaccines in Canada

In a recent study posted to the medRxiv* preprint server, researchers evaluated the efficacy and safety of the coronavirus disease 2019 (COVID-19) vaccines in young and elderly cohorts from Canada.

14 Feb 2022

Immunoglobulin News and Research

Pre-existing B-cell immunity against SARS-CoV-2 not detected in pre-pandemic samples

New approach for extensive screening of monoclonal antibody clones against multiple myeloma cells

Lung microbiome alterations and secondary-infections in lethal COVID-19

Study suggests anti-SARS-CoV-2 antibodies may persist lifelong post-infection

Using IgG antibody assay to Identify natural SARS-CoV-2 infection in vaccinees

Novel ACE2-blocking antibody protects against all SARS-CoV-2 VOCs

Study reports potently neutralizing mucosal IgA in saliva of BNT162b2 vaccine recipients

Mathematical model of host immune response to SARS-CoV-2 demonstrates that age-related risk factors increased viral load

Inhalable antibody fragments offer broad protection from SARS-CoV-2 variants

Mechanism of fatty-acid coupled adaptive immunity in SARS-CoV-2 revealed

Immunogenicity, efficacy, and safety of BNT162b2 or mRNA1273 fourth dose

Study explores humoral and cellular immunity conferred by second and third COVID-19 BNT162b2 vaccination in elderly

mRNA COVID-19 vaccine shown to induce afucosylated antibodies in individuals without prior SARS-CoV-2 exposure

Memory B cell repertoire in a longitudinal cohort of individuals receiving 3 COVID-19 mRNA vaccine doses

Children with severe COVID-19 show low mucosal neutralizing activity against SARS-CoV-2

Features of platelet-immune crosstalk in healthy recipients of two doses of mRNA-based SARS-CoV-2 vaccine BNT162b2

Neutralizing antibody levels to different SARS-CoV-2 epitopes fluctuate over time

Canadian study estimates incidence rate of reinfection in healthcare workers

Post-vaccination titers of neutralizing antibodies revealed as a moderate predictor of vaccine-induced immunity

Real-world data on efficacy and safety of COVID vaccines in Canada

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News